Establishes a drug-induced movement disorder screening education program; provides that the department shall develop such program to educate the public about the importance of screening for drug-induced movement disorders, develop and disseminate educational materials for healthcare providers regarding treatment for drug-induced movement disorders, and eliminate bias and reduction of stigma for people living with drug-induced movement disorders related to the treatment of mental health conditions.
NEW YORK STATE ASSEMBLY MEMORANDUM IN SUPPORT OF LEGISLATION submitted in accordance with Assembly Rule III, Sec 1(f)
BILL NUMBER: A6799B
SPONSOR: Paulin TITLE OF BILL:
An act to amend the public health law, in relation to establishing a
drug-induced movement disorder screening education program
PURPOSE OR GENERAL IDEA OF BILL:
The purpose of this legislation is to provide educational information
about the importance of screening for and recognizing symptoms of drug-
induced movement disorders, develop guidance on clinical standards for
treating drug-induced movement disorders including via telehealth, and
the elimination of bias and reduction of stigma for people living with
drug-induced movement disorders related to the treatment of mental
health conditions.
SUMMARY OF PROVISIONS:
Section 1 includes the legislative intent.
Section 2 requires the New York State Department of Health to establish
a drug-induced movement disorder screening and awareness program within
the department under the health care and wellness education and outreach
program. The program will promote education and awareness of drug-in-
duced movement disorders and screening of these disorders. It will
include the development and dissemination of educational materials for
health care providers regarding the treatment for drug-induced movement
disorders. These educational materials must be developed in coordination
with relevant health care provider groups.
Section 3 of this bill is the effective date of 90 days after it shall
become a law.
JUSTIFICATION:
Patients receiving treatment with medications for their mental health
conditions may be at risk of developing a drug-induced movement disor-
der. Drug-induced movement disorders, as discussed in the most recent
edition of the Diagnostic and Statistical Manual of Mental
Disorders(DSM-5), are of "frequent importance" when mental disorders and
other medical conditions are managed with antipsychotic medications.
These involuntary movement disorders are caused by medications that help
control dopamine, such as first- and second-generation antipsychotics
commonly prescribed to treat people living with mental illnesses like
schizophrenia, bipolar disorder, and major depression. Some drug-induced
movement disorders, such as tardivedyskinesia; are persistent, irrevers-
ible, potentially disabling neurological conditions characterized by
uncontrollable repetitive movements of the face, torso, or other parts
of the body. While untreated involuntary movements can be stigmatizing
and debilitating, the rates of undiagnosed patients living with drug-in-
duced movement disorders remains high.
Awareness of and periodic screenings for movement disorders are funda-
mental to the proper identification, diagnosis, and timely treatment of
drug-induced movement disorders. Recent updates to the American Psychi-
atric Association's clinical guidelines reflect the importance of
screening in people at risk of developing drug-induced movement disor-
ders, but health care and mental health providers, patients, and the
public may be unaware of these standards.
Under this bill, the Department of Health, through the health care and
wellness education and outreach program will provide educational infor-
mation to educate providers and the public on the importance of screen-
ing and recognizing symptoms of drug-induced movement disorders, develop
clinical guidance for treating drug-induced movement disorders including
the use of telehealth, and to provide education and outreach on the
elimination of stigma associated with drug-induced involuntary move-
ments. As part of this program, the Department should inventory existing
drug-induced movement disorder resources available, develop and maintain
educational materials and guidance for providers and the public, and
help develop training for public safety officials to recognize drug-in-
duced movement disorders.
Public education and information about drug-induced movement disorders
will help health professionals, public safety officials, and the commu-
nity better understand these disorders, including what causes these
types of involuntary movements and their prevalence. This can help
reduce stigma by clarifying that some abnormal movements that may be
mistaken as a public safety concern are actually uncontrollable physical
symptoms of conditions caused by medication used to treat mental
illness.
In addition, services provided via telehealth to patients at risk of
developing drug-induced movement disorders, such as those treated with
antipsychotic medications, should align with existing clinical standards
of care. This includes ensuring that at-risk patients are periodically
screened and assessed for developing drug-induced movement disorders.
The needs of patients living with or at risk of developing drug-induced
movement disorders encompass both mental and physical health care, and
therefore may require additional considerations when determining the
clinical appropriateness of telehealth.
PRIOR LEGISLATIVE HISTORY:
New bill.
FISCAL IMPLICATIONS FOR STATE AND LOCAL GOVERNMENTS:
Minimal as this program will be included in the already existing Depart-
ment of Health healthcare and wellness education and outreach program.
EFFECTIVE DATE:
This bill shall take effect on the 90th day after it shall have become a
law. Effective immediately, the addition, amendment and/or repeal of any
rule or regulation necessary for the implementation of this act on its
effective date are authorized to be made and completed on or before such
effective date.
STATE OF NEW YORK
________________________________________________________________________
6799--B
2023-2024 Regular Sessions
IN ASSEMBLY
May 8, 2023
___________
Introduced by M. of A. PAULIN, SAYEGH, SEAWRIGHT -- read once and
referred to the Committee on Health -- committee discharged, bill
amended, ordered reprinted as amended and recommitted to said commit-
tee -- recommitted to the Committee on Health in accordance with
Assembly Rule 3, sec. 2 -- committee discharged, bill amended, ordered
reprinted as amended and recommitted to said committee
AN ACT to amend the public health law, in relation to establishing a
drug-induced movement disorder screening education program
The People of the State of New York, represented in Senate and Assem-bly, do enact as follows:
1 Section 1. Subdivision 1 of section 207 of the public health law is
2 amended by adding a new paragraph (h) to read as follows:
3 (h) The department shall develop and conduct a program concerning
4 drug-induced movement disorders. Such program shall include but not be
5 limited to, (i) educational information on the importance of screening
6 for and identifying symptoms of drug-induced movement disorders; and
7 (ii) the development and dissemination of educational materials for
8 healthcare providers regarding treatment for drug-induced movement
9 disorders, including for services provided via telehealth. Such educa-
10 tional materials disseminated to healthcare providers shall be developed
11 and disseminated in coordination with relevant healthcare provider
12 groups and shall include best practices for the treatment and screening
13 of movement disorders informed by the American Psychiatric Association
14 and other professional society practice guidelines. Such program shall
15 also include education and outreach on the elimination of stigma for
16 people living with drug-induced movement disorders related to the treat-
17 ment of mental health conditions.
18 § 2. This act shall take effect on the ninetieth day after it shall
19 have become a law. Effective immediately, the addition, amendment and/or
20 repeal of any rule or regulation necessary for the implementation of
21 this act on its effective date are authorized to be made and completed
22 on or before such effective date.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[] is old law to be omitted.
LBD10964-05-4
